TCTN2

Across TCGA pan-cancer cohorts, TCTN2 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of TCTN2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where TCTN2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TCTN2 is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

BLCA, KIRC, and KICH are the cancer types where TCTN2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TCTN2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	+1.044	<.001	11	view →
KIRC	Male	All	+0.430	<.001	11	view →
KICH	Female	II,III,IV	−2.087	<.001	10	view →
THCA	Male	All	−0.812	<.001	10	view →
HNSC	Male	III,IV	+1.014	<.001	8	view →
COAD	Female	II,III,IV	+0.924	<.001	8	view →
LIHC	All	II,III,IV	+0.884	<.001	8	view →
KIRP	All	II,III,IV	+0.807	.001	7	view →
CHOL	All	All	+3.557	<.001	5	view →
STAD	Male	All	+0.646	.002	5	view →
READ	All	III,IV	+1.199	.037	3	view →
ESCA	All	All	+0.778	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

TCTN2–BLCA

Open the BLCA breakdown →